Dr. Mann on Immunotherapy Developments in Prostate Cancer

Mark J. Mann, MD
Published: Monday, Mar 19, 2018



Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the future of immunotherapy in prostate cancer.

According to Mann, sipuleucel-T (Provenge) was far ahead of the curve when it was first developed and approved. From the approval of sipuleucel-T and other immunotherapies, physicians have learned that evaluating outcomes based purely on prostate-specific antigen (PSA) values can be misleading.

In PD-L1 inhibitors, there may be a response that is not reflected radiographically; there may be a swelling and flare effect. It’s reasonable to expect that in immunotherapies. This may be why sipuleucel-T was not as broadly adopted when it was approved, he adds.

More recent immunotherapies have shown modest efficacy. Now that physicians understand radiographic flares or PSA values may not be indicative of efficacy, we may be able to evaluate outcome markers such as metastasis-free survival, the same markers that the apalutamide (Erleada) and enzalutamide (Xtandi) studies used as primary endpoints.
 
SELECTED
LANGUAGE


Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the future of immunotherapy in prostate cancer.

According to Mann, sipuleucel-T (Provenge) was far ahead of the curve when it was first developed and approved. From the approval of sipuleucel-T and other immunotherapies, physicians have learned that evaluating outcomes based purely on prostate-specific antigen (PSA) values can be misleading.

In PD-L1 inhibitors, there may be a response that is not reflected radiographically; there may be a swelling and flare effect. It’s reasonable to expect that in immunotherapies. This may be why sipuleucel-T was not as broadly adopted when it was approved, he adds.

More recent immunotherapies have shown modest efficacy. Now that physicians understand radiographic flares or PSA values may not be indicative of efficacy, we may be able to evaluate outcome markers such as metastasis-free survival, the same markers that the apalutamide (Erleada) and enzalutamide (Xtandi) studies used as primary endpoints.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x